Pleiotropic Actions of the Incretin Hormones

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 21-79

  McIntosh, Christopher H S ^a   Widenmaier, Scott ^a   Kim, Su Jin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell; Adipose; Apoptosis; Cardiovascular; Differentiation; Food intake; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin; Insulin secretion

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; INSULIN;

ANIMAL; BOOK; HUMAN; PANCREAS ISLET; PHYSIOLOGY; SECRETION;

ANIMALS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS; RECEPTORS, GLUCAGON;

EID: 78649429475     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00002-3     Document Type: Book

References (386)

1. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R.C., Ghatei M.A., Bloom S.R. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044:127-131.
2. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009, 94:1843-1852.
3. Acitores A., Gonzalez N., Sancho V., Valverde I., Villanueva-Penacarrillo M.L. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J. Endocrinol. 2004, 180:389-398.
4. Adrian T.E., Bloom S.R., Hermansen K., Iversen J. Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas. Diabetologia 1978, 14:413-417.
5. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:R269-R272.
6. Alarcon C., Wicksteed B., Rhodes C.J. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006, 49:2920-2929.
7. Andersen D.K., Elahi D., Brown J.C., Tobin J.D., Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J. Clin. Invest. 1978, 62:152-161.
8. Anvari M., Paterson C.A., Daniel E.E., McDonald T.J. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig. Dis. Sci. 1998, 43:1133-1140.
9. Asarian L., Corp E.S., Hrupka B., Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol. Behav. 1998, 64:367-372.
10. Ashcroft F., Rorsman P. Molecular defects in insulin secretion in type-2 diabetes. Rev. Endocr. Metab. Disord. 2004, 4:135-142.
11. Ayala J.E., Bracy D.P., James F.D., Julien B.M., Wasserman D.H., Drucker D.J. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009, 150:1155-1164.
12. Baggio L.L., Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu. Rev. Med. 2006, 57:265-281.
13. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
14. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
15. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
16. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R1449-R1454.
17. Ban N., Yamada Y., Someya Y., Ihara Y., Adachi T., Kubota A., Watanabe R., Kuroe A., Inada A., Miyawaki K., Sunaga Y., Shen Z.-P., et al. Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes 2000, 49:1142-1148.
18. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.-S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
19. Bao S., Bohrer A., Ramanadham S., Jin W., Zhang S., Turk J. Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J. Biol. Chem. 2006, 281:187-198.
20. Bao S., Song H., Wohltmann M., Ramanadham S., Wu J., Bohrer A., Turk J. Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express group VIA phospholipase A2 and the effect of metabolic stress on glucose homeostasis. J. Biol. Chem. 2006, 281:20958-20973.
21. Barragán J.M., Rodríguez R.E., Blazquéz E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol. Cell Physiol. 1994, 266:E459-E466.
22. Barragán J.M., Eng J., Rodríguez R.E., Blásquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol. Endocrinol. Metab. 1999, 277:E784-E791.
23. Bayliss W., Starling E. The mechanism of pancreatic secretion. J. Physiol. 1902, 28:325-352.
24. Bell G.I., Santerre R.F., Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983, 302:716-718.
25. Benito E., Blazquez E., Bosch M.A. Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3', 5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. Endocrinology 1998, 139:2363-2368.
26. Bertin E., Arner P., Bolinder J., Hagstrom-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J. Clin. Endocrinol. Metab. 2001, 86:1229-1234.
27. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res. 2008, 33:1845-1851.
28. Blackmore P.F., Mojsov S., Exton J.H., Habener J.F. Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes. FEBS Lett. 1991, 283:7-10.
29. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., Mulloy A.L., Rasmussen H., Qin F., Ding K.H., Isales C.M. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000, 141:1228-1235.
30. Bollag R.J., Zhong Q., Ding K.H., Phillips P., Zhong L., Qin F., Cranford J., Mulloy A.L., Cameron R., Isales C.M. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol. Cell. Endocrinol. 2001, 177:35-41.
31. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
32. Bose A.K., Mocanu M.M., Carr R.D., Yellon D.M. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther. 2005, 19:9-11.
33. Brown J.C. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can. J. Biochem. 1971, 49:255-261.
34. Brown J.C., Dryburgh J.R. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can. J. Biochem. 1971, 49:867-872.
35. Brown J.C., Pederson R.A. GI hormones and insulin secretion. Endocrinol. Proc. 5th Int. Congr. Endocrinol. 1976, 2:568-570.
36. Brown J.C., Dryburgh J.R., Ross S.A., Dupre J. Identification and actions of gastric inhibitory polypeptide. Rec. Prog. Horm. Res. 1975, 31:487-532.
37. Brubaker P.L. The glucagon-like peptides: Pleiotropic regulators of nutrient homeostasis. Ann. NY Acad. Sci. 2006, 1070:10-26.
38. Brubaker P.L., Drucker D.J. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004, 145:2653-2659.
39. Brun T., He K.H.H., Lupi R., Boehm B., Wojtusciszyn A., Sauter N., Donath M., Marchetti P., Maedler K., Gauthier B.R. The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Hum. Mol. Genet. 2008, 17:478-489.
40. Brunicardi F.C., Druck P., Seymour N.E., Sun Y.S., Elahi D., Andersen D.K. Selective neurohormonal interactions in islet cell secretion in the isolated perfused human pancreas. J. Surg. Res. 1990, 48:273-278.
41. Buhren B.A., Gasis M., Thorens B., Muller H.W., Bosse F. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): Cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J. Neurosci. Res. 2009, 87:1858-1870.
42. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
43. Burcelin R., Da Costa A., Drucker D., Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001, 50:1720-1728.
44. Buteau J. GLP-1 receptor signaling: Effects on pancreatic beta-cell proliferation and survival. Diabetes Metab. 2008, 34(Suppl. 2):S73-S77.
45. Buteau J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β- (INS-1)-cells. Diabetologia 1999, 42:856-864.
46. Buteau J., Foisy S., Rhodes C.J., Carpenter L., Biden T.J., Prentki M. Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 2001, 50:2237-2243.
47. Buteau J., Foisy S., Joly E., Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003, 52:124-132.
48. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47:806-815.
49. Buteau J., Spatz M.L., Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006, 55:1190-1196.
50. Castresana M., Lee K.Y., Chey W.Y., Yajima H. Effects of motilin and octapeptide of cholecystokinin on antral and duodenal myoelectric activity in the interdigestive state and during inhibition by secretin and gastric inhibitory polypeptide. Digestion 1978, 17:300-308.
51. Cheeseman C. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-1 infusion in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1997, 273:R1965-R1971.
52. Cheeseman C.I., O'Neill D. Basolateral d-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Exp. Physiol. 1998, 83:605-616.
53. Cheeseman C.I., Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am. J. Physiol. 1996, 271:G477-G482.
54. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1695-R1706.
55. Chepurny O.G., Hussain M.A., Holz G.G. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Endocrinology 2002, 143:2303-2313.
56. Cornu M., Yang J.-Y., Jaccard E., Poussin C., Widmann C., Thorens B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 2009, 58:1816-1825.
57. Cornu M., Modi H., Kawamori D., Kulkarni R.N., Joffraud M., Thorens B. Glucagon-like peptide-1 (GLP-1) increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor (IGF-1R) expression. J. Biol. Chem. 2010, 285:10538-10545.
58. Creutzfeldt W. The incretin concept today. Diabetologia 1979, 16:75-85.
59. Creutzfeldt W. The [pre-] history of the incretin concept. Regul. Pept. 2005, 128:87-91.
60. Cunha D.A., Ladriere L., Ortis F., Igoillo-Esteve M., Gurzov E.N., Lupi R., Marchetti P., Eizirik D.L., Cnop M. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009, 58:2851-2862.
61. Cure P., Pileggi A., Alejandro R. Exenatide and rare adverse events. N Engl. J. Med. 2008, 358:1970-1971.
62. D'Alessio D.A., Kahn S.E., Leusner C.R., Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 1994, 93:2263-2266.
63. D'Alessio D., Vahl T., Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm. Metab. Res. 2004, 36:837-841.
64. Dardevet D., Moore M.C., Neal D., DiCostanzo C.A., Snead W., Cherrington A.D. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: Duration of infusion and involvement of hepatoportal region. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E75-E81.
65. Dardevet D., Moore M.C., DiCostanzo C.A., Farmer B., Neal D.W., Snead W., Lautz M., Cherrington A.D. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G806-G814.
66. de Heer J., Rasmussen C., Coy D.H., Holst J.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008, 51:2263-2270.
67. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr. Med. Res. Opin. 2008, 24:2943-2952.
68. Delgado-Aros S., Kim D.-Y., Burton D.D., Thomforde G.M., Stephens D., Brinkmann B.H., Vella A., Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G424-G431.
69. Delmeire D., Flamez D., Moens K., Hinke S.A., Van Schravendijk C., Pipeleers D., Schuit F. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem. Pharmacol. 2004, 68:33-39.
70. Denniss A.R., Young J.A. Modification of salivary duct electrolyte transport in rat and rabbit by physalaemin, VIP, GIP and other enterohormones. Pflügers Arch. Eur. J. Physiol. 1978, 376:73-80.
71. Ding W.G., Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997, 46:615-621.
72. 2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997, 46:792-800.
73. Ding K.-H., Zhong Q., Xu J., Isales C.M. Glucose-dependent insulinotropic peptide: Differential effects on hepatic artery vs. portal vein endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E773-E779.
74. Ding K.-H., Zhong Q., Xu J., Isales C.M. Glucose-dependent insulinotropic peptide: Differential effects on hepatic artery vs. portal vein endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E773-E779.
75. Ding K.-H., Shi X.-M., Zhong Q., Kang B., Xie D., Bollag W.B., Bollag R.J., Hill W., Washington W., Mi Q.-S., Insogna K., Chutkan N., et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J. Bone Miner. Res. 2008, 23:536-543.
76. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
77. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
78. Drucker D. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 2007, 117:24-32.
79. Drucker D.J., Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
80. Drucker D., Philippe J., Mojsov S., Chick W., Habener J. Glucagon-like I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 1987, 84:3434-3438.
81. Dunning B.E., Gerich J.E. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 2007, 28:253-283.
82. Dunning B.E., Foley J.E., Ahren B. Alpha cell function in health and disease: Influence of glucagon-like peptide-1. Diabetologia 2005, 48:1700-1713.
83. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9:1173-1179.
84. Egan J.M., Meneilly G.S., Habener J.F., Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J. Clin. Endocrinol. Metab. 2002, 87:3768-3773.
85. Ehses J.A., Lee S.S., Pederson R.A., McIntosh C.H. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: Evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J. Biol. Chem. 2001, 276:23667-23673.
86. Ehses J.A., Pelech S.L., Pederson R.A., McIntosh C.H. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J. Biol. Chem. 2002, 277:37088-37097.
87. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Winter K.D., Demuth H.U., Pederson R.A., McIntosh C.H. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003, 144:4433-4445.
88. Elahi D., Andersen D.K., Brown J.C., Debas H.T., Hershcopf R.J., Raizes G.S., Tobin J.D., Andres R. Pancreatic alpha- and beta-cell responses to GIP infusion in normal man. Am. J. Physiol. 1979, 237:E185-E191.
89. Elahi D., Egan J.M., Shannon R.P., Meneilly G.S., Khatri A., Habener J.F., Andersen D.K. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008, 16:1501-1509.
90. Eliasson L., Ma X., Renstrom E., Barg S., Berggren P.-O., Galvanovskis J., Gromada J., Jing X., Lundquist I., Salehi A., Sewing S., Rorsman P. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic Β-cells. J. Gen. Physiol. 2003, 121:181-197.
91. Elrick H., Stimmler L., Hlad C.J., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
92. Fara J.W., Salazar A.M. Gastric inhibitory polypeptide increases mesenteric blood flow. Proc. Soc. Exp. Biol. Med. 1978, 158:446-448.
93. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143:4397-4408.
94. Faruque O.M., Le-Nguyen D., Lajoix A.-D., Vives E., Petit P., Bataille D., Hani E.-H. Cell-permeable peptide-based disruption of endogenous PKA-AKAP complexes: A tool for studying the molecular roles of AKAP-mediated PKA subcellular anchoring. Am. J. Physiol. Cell Physiol. 2009, 296:C306-C316.
95. Fehmann H.C., Göke B. Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 1995, 16:1149-1152.
96. Fehmann H.C., Hering B.J., Wolf M.J., Brandhorst H., Brandhorst D., Bretzel R.G., Federlin K., Göke B. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 1995, 11:196-200.
97. Feng X.-H., Liu X.-M., Zhou L.-H., Wang J., Liu G.-D. Expression of glucagon-like peptide-1 in the taste buds of rat circumvallate papillae. Acta Histochem. 2008, 110:151-154.
98. Ferdaoussi M., Abdelli S., Yang J.-Y., Cornu M., Niederhauser G., Favre D., Widmann C., Regazzi R., Thorens B., Waeber G., Abderrahmani A. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008, 57:1205-1215.
99. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998, 101:515-520.
100. Flint A., Raben A., Ersboll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metab. Disord. 2001, 25:781-792.
101. Franklin I., Gromada J., Gjinovci A., Theander S., Wollheim C.B. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 2005, 54:1808-1815.
102. Fraser I.D., Tavalin S.J., Lester L.B., Langeberg L.K., Westphal A.M., Dean R.A., Marrion N.V., Scott J.D. A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events. EMBO J. 1998, 17:2261-2272.
103. 2+ and G protein-coupled receptors in the pancreatic beta-cell: A computational approach. Am. J. Physiol. Cell Physiol. 2007, 294:C1924-C1933.
104. Fridolf T., Bottcher G., Sundler F., Ahrén B. GLP-1 and GLP-1(7-36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 1991, 6:208-215.
105. Friedrichsen B.N., Neubauer N., Lee Y.C., Gram V.K., Blume N., Petersen J.S., Nielsen J.H., Moldrup A. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J. Endocrinol. 2006, 188:481-492.
106. Fürnsinn C., Ebner K., Waldhäusl W. Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 1995, 38:864-867.
107. Gao H., Wang X., Zhang Z., Yang Y., Yang J., Li X., Ning G. GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocr. Rev. 2007, 32:90-95.
108. Gardiner S.M., March J.E., Kemp P.A., Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J. Pharmacol. Exp. Ther. 2006, 316:852-859.
109. Getty-Kaushik L., Song D.H., Boylan M.O., Corkey B.E., Wolfe M.M. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006, 14:1124-1131.
110. Ghiglione M., Blazquez E., Uttenthal L.O., de Diego J.G., Alvarez E., George S.K., Bloom S.R. Glucagon-like peptide-1 does not have a role in hepatic carbohydrate metabolism. Diabetologia 1985, 28:920-921.
111. Goldstone A.P., Mercer J.G., Gunn I., Moar K.M., Edwards C.M., Rossi M., Howard J.K., Rasheed S., Turton M.D., Small C., Heath M.M., O'Shea D., et al. Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett. 1997, 415:134-138.
112. Goldstone A.P., Morgan I., Mercer J.G., Morgan D.G., Moar K.M., Ghatei M.A., Bloom S.R. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem. Biophys. Res. Commun. 2000, 269:331-335.
113. Golpon H.A., Puechner A., Welte T., Wichert P.V., Feddersen C.O. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul. Pept. 2001, 102:81-86.
114. Gomez E., Pritchard C., Herbert T.P. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J. Biol. Chem. 2002, 277:48146-48151.
115. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch. Biochem. Biophys. 2008, 478:136-142.
116. Gromada J., Holst J.J., Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch. 1998, 435:583-594.
117. Gromada J., Brock B., Schmitz O., Rorsman P. Glucagon-like peptide-1: Regulation of insulin secretion and therapeutic potential. Basic Clin. Pharmacol. Toxicol. 2004, 95:252-262.
118. Gromada J., Franklin I., Wollheim C.B. α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 2007, 28:84-116.
119. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker D.J., Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
120. Gunn I., O'Shea D., Turton M.D., Beak S.A., Bloom S.R. Central glucagon-like peptide-I in the control of feeding. Biochem. Soc. Trans. 1996, 24:581-584.
121. Gutzwiller J.P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J., Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 1999, 276:R1541-R1544.
122. Gutzwiller J.P., Göke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., Beglinger C. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999, 44:81-86.
123. Hadjiyanni I., Siminovitch K.A., Danska J.S., Drucker D.J. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010, 53:730-740.
124. Hansen B.F., Jensen P., Nepper-Christensen E., Skjolstrup B. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol. 1998, 35:101-103.
125. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
126. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004, 53:1326-1335.
127. Hartmann H., Ebert R., Creutzfeldt W. Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver. Diabetologia 1986, 29:112-114.
128. Hauge-Evans A.C., King A.J., Carmignac D., Richardson C.C., Robinson I.C.A.F., Low M.J., Christie M.R., Persaud S.J., Jones P.M. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009, 58:403-411.
129. Hauner H., Glatting G., Kaminska D., Pfeiffer E.F. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann. Nutr. Metab. 1988, 32:282-288.
130. Hay C.W., Sinclair E.M., Bermano G., Durward E., Tadayyon M., Docherty K. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. J. Endocrinol. 2005, 186:353-365.
131. Hayes M.R., Bradley L., Grill H.J., Hayes M.R., Bradley L., Grill H.J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009, 150:2654-2659.
132. Heller R.S., Kieffer T.J., Habener J.F. Insulinotropic glucagon-like peptide 1 receptor expression in glucagon,-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997, 46:785-791.
133. Hellström P.M., Näslund E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol. Behav. 2001, 74:735-741.
134. Hellström P.M., Näslund E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol. Behav. 2001, 74:735-741.
135. Helman C.A., Barbezat G.O. The effect of gastric inhibitory polypeptide on human jejunal water and electrolyte transport. Gastroenterology 1977, 72:376-379.
136. Hinke S.A., Hellemans K., Schuit F.C. Plasticity of the beta cell insulin secretory competence: Preparing the pancreatic beta cell for the next meal. J. Physiol. (Lond.) 2004, 558:369-380.
137. Hiriart M., Aguilar-Bryan L. Channel regulation of glucose sensing in the pancreatic beta-cell. Am. J. Physiol. Endocrinol. Metab. 2008, 295:1298-1306.
138. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87:1409-1439.
139. Holst J.J., Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48:612-615.
140. Holst J.J., Ørskov C., Nielsen O.V., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987, 211:169-174.
141. Holz G.G. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004, 53:5-13.
142. Holz G.G., Chepurny O.G. Diabetes outfoxed by GLP-1?. Sci. STKE 2005, pe2.
143. Holz G.G.T., Kuhtreiber W.M., Habener J.F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993, 361:362-365.
144. Holz G.G., Kang G., Harbeck M., Roe M.W., Chepurny O.G. Cell physiology of cAMP sensor Epac. J. Physiol. 2006, 577:5-15.
145. Holz G.G., Heart E., Leech C.A. Synchronizing Ca2+ and cAMP oscillations in pancreatic beta-cells: A role for glucose metabolism and GLP-1 receptors? Focus on "regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic beta-cell: A computational approach". Am. J. Physiol. Cell Physiol. 2008, 294:C4-C6.
146. Huda M.S.B., Wilding J.P.H., Pinkney J.H. Gut peptides and the regulation of appetite. Obes. Rev. 2006, 7:163-182.
147. Hui H., Nourparvar A., Zhao X., Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003, 144:1444-1455.
148. Huo L., Gamber K., Greeley S., Silva J., Huntoon N., Leng X.-H., Bjorbaek C. Leptin-dependent control of glucose balance and locomotor activity by POMC neurons. Cell Metab. 2009, 9:537-547.
149. Huypens P., Ling Z., Pipeleers D., Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000, 43:1012-1019.
150. Idris I., Patiag D., Gray S., Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: Contrasting effects of GLP-1. Biochem. Pharmacol. 2002, 63:993-996.
151. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. 1997, 273:G920-G927.
152. Ionut V., Zheng D., Stefanovski D., Bergman R.N. Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E269-E277.
153. Ipp E., Dobbs R.E., Harris V., Arimura A., Vale W., Unger R.H. The effects of gastrin, gastric inhibitory polypeptide, secretin, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas. J. Clin. Invest. 1977, 60:1216-1219.
154. Jacobo S.M.P., Guerra M.L., Hockerman G.H. Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1. J. Pharmacol. Exp. Ther. 2009, 331:724-732.
155. Jacobson D.A., Weber C.R., Bao S., Turk J., Philipson L.H. Modulation of the pancreatic islet β-cell-delayed rectifier potassium channel Kv2.1 by the polyunsaturated fatty acid arachidonate. J. Biol. Chem. 2007, 282:7442-7449.
156. Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J., Walker J., Lin X., White M., Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003, 17:1575-1780.
157. Jia X., Brown J.C., Ma P., Pederson R.A., McIntosh C.H. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am. J. Physiol. 1995, 268:E645-E651.
158. Jin S.L., Han V.K., Simmons J.G., Towle A.C., Lauder J.M., Lund P.K. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: An immunocytochemical study. J. Comp. Neurol. 1988, 271:519-532.
159. Johnson K.M.S., Edgerton D.S., Rodewald T., Scott M., Farmer B., Neal D., Cherrington A.D. Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E380-E384.
160. 2+ release and exocytosis in pancreatic beta-cells. J. Biol. Chem. 2003, 278:8279-8285.
161. Kang G., Chepurny O.G., Rindler M.J., Collis L., Chepurny Z., Li W.-H., Harbeck M., Roe M.W., Holz G.G. A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells. J. Physiol. (Lond.) 2005, 566:173-188.
162. Kang G., Chepurny O.G., Malester B., Rindler M.J., Rehmann H., Bos J.L., Schwede F., Coetzee W.A., Holz G.G. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J. Physiol. (Lond.) 2006, 573:595-609.
163. Kang G., Leech C.A., Chepurny O.G., Coetzee W.A., Holz G.G. Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells. J. Physiol. (Lond.) 2008, 586:1307-1319.
164. Kanse S.M., Kreymann B., Ghatei M.A., Bloom S.R. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett. 1988, 241:209-212.
165. Kashima Y., Miki T., Shibasaki T., Ozaki N., Miyazaki M., Yano H., Seino S. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. 2001, 276:46046-46053.
166. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
167. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512.
168. Kim S.-J., Choi W.S., Han J.S.M., Warnock G., Fedida D., McIntosh C.H.S. A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: Protein kinase A-dependent endocytosis. J. Biol. Chem. 2005, 280:28692-28700.
169. Kim S.-J., Winter K., Nian C., Tsuneoka M., Koda Y., McIntosh C.H.S. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J. Biol. Chem. 2005, 280:22297-22307.
170. Kim M.J., Kang J.H., Park Y.G., Ryu G.R., Ko S.H., Jeong I.K., Koh K.H., Rhie D.J., Yoon S.H., Hahn S.J., Kim M.S., Jo Y.H. Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: Involvement of cAMP-responsive element. J. Endocrinol. 2006, 188:623-633.
171. Kim S.-J., Nian C., McIntosh C.H.S. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J. Biol. Chem. 2007, 282:8557-8567.
172. Kim S.-J., Nian C., McIntosh C.H.S. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J. Biol. Chem. 2007, 282:34139-34147.
173. 2+ signal that is essential for insulin secretion in mouse pancreatic islets. Diabetes 2008, 57:868-878.
174. Kim S.-J., Nian C., Widenmaier S., McIntosh C.H.S. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol. Cell. Biol. 2008, 28:1644-1656.
175. Kim D.H., D'Alessio D.A., Woods S.C., Seeley R.J., Kim D.-H., D'Alessio D.A., Woods S.C., Seeley R.J. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul. Pept. 2009, 155:110-114.
176. Kim S.-J., Nian C., McIntosh C.H.S. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J. Biol. Chem. 2009, 284:12896-12904.
177. + T cell migration through incretin-dependent and -independent pathways. Diabetes 2010, (Published online April 5, 2010). 10.2337/db09-1618.
178. Kinzig K.P., D'Alessio D.A., Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 2002, 22:10470-10476.
179. Kirchgessner A., Gershon M.D. Innervation of the pancreas by neurons in the gut. J. Neurosci. 1990, 10:1626-1642.
180. Kissler H.J., Gepp H., Schmiedl A., Schwille P.O. Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats. Metabolism 1999, 48:645-650.
181. Klinger S., Poussin C., Debril M.-B., Dolci W., Halban P.A., Thorens B. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 2008, 57:584-593.
182. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., Benhamed F., Gremeaux T., Drucker D.J., Kahn C.R., Girard J., Tanti J.F., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.[see comment]. J. Clin. Invest. 2005, 115:3554-3563.
183. Knauf C., Cani P.D., Kim D.-H., Iglesias M.A., Chabo C., Waget A., Colom A., Rastrelli S., Delzenne N.M., Drucker D.J., Seeley R.J., Burcelin R. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes 2008, 57:2603-2612.
184. Knoch K.-P., Meisterfeld R., Kersting S., Bergert H., Altkruger A., Wegbrod C., Jager M., Saeger H.-D., Solimena M. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab. 2006, 3:123-134.
185. Koehler J.A., Baggio L.L., Lamont B.J., Ali S., Drucker D.J. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009, 58:2148-2161.
186. Kogire M., Inoue K., Sumi S., Doi R., Takaori K., Yun M., Fujii N., Yajima H., Tobe T. Effects of synthetic human gastric inhibitory polypeptide on splanchnic circulation in dogs. Gastroenterology 1988, 95:1636-1640.
187. Kogire M., Inoue K., Sumi S., Doi R., Yun M., Kaji H., Tobe T. Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. Dig. Dis. Sci. 1992, 37:1666-1670.
188. Kolligs F., Fehmann H.C., Göke R., Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995, 44:16-19.
189. Konturek S., Bilski J., Tasler J., Laskiewicz L. Gut hormones in stimulation of gastroduodenal alkaline secretion in conscious dogs. Am. J. Physiol. Gastrointest. Liver Physiol. 1985, 248:G687-G691.
190. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987, 2:1300-1304.
191. La Barre J. Sur les possibilités d'un traitement du diabète par l'incrétine. Bull. Acad. R. Méd. Belg. 1932, 12:620-634.
192. Lachey J.L., D'Alessio D.A., Rinaman L., Elmquist J.K., Drucker D.J., Seeley R.J. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: Differential effects in rats and mice. Endocrinology 2005, 146:458-462.
193. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
194. Larsen P.J., Fledelius C., Knudsen L.B., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
195. Lawrence M.C., Bhatt H.S., Easom R.A. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 2002, 51:691-698.
196. Lester L.B., Faux M.C., Nauert J.B., Scott J.D. Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation. Endocrinology 2001, 142:1218-1227.
197. Leturque A., Brot-Laroche E., Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E985-E992.
198. Lewis J.T., Dayanandan B., Habener J.F., Kieffer T.J. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 2000, 141:3710-3716.
199. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
200. Li Y., Cao X., Li L.-X., Brubaker P.L., Edlund H., Drucker D.J. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005, 54:482-491.
201. Light P.E., Manning Fox J.E., Riedel M.J., Wheeler M.B. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol. Endocrinol. 2002, 16:2135-2144.
202. Ling Z., Wu D., Zambre Y., Flamez D., Drucker D.J., Pipeleers D.G., Schuit F.C. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001, 438:382-387.
203. List J.F., Habener J.F. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E875-E881.
204. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 2008, 283:8723-8735.
205. Lu M., Wheeler M.B., Leng X.H., Boyd A.E. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 1993, 132:94-100.
206. Lund P.K. The discovery of glucagon-like peptide 1. Regul. Pept. 2005, 128:93-96.
207. Lund P.K., Goodman R.H., Dee P.C., Habener J.F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc. Natl. Acad. Sci. USA 1982, 79:345-349.
208. + channels in pancreatic beta cells: Role, regulation and potential as therapeutic targets. Diabetologia 2003, 46:1046-1062.
209. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M.F., Light P.E., Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002, 51(Suppl. 3):S434-S442.
210. + currents in beta-cells: A possible glucose-dependent insulinotropic mechanism. Diabetes 2002, 51(Suppl. 3):S443-S447.
211. + channels in pancreatic beta-cells enhances glucose-dependent insulin secretion. J. Biol. Chem. 2002, 277:44938-44945.
212. MacDonald P.E., Wang X., Xia F., El-kholy W., Targonsky E.D., Tsushima R.G., Wheeler M.B. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J. Biol. Chem. 2003, 278:52446-52453.
213. Mafong D.D., Henry R.R. The role of incretins in cardiovascular control. Curr. Hypertens. Rep. 2009, 11:18-22.
214. Maida A., Hansotia T., Longuet C., Seino Y., Drucker D.J. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009, 137:2146-2157.
215. Mattoon D.R., Lamothe B., Lax I., Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2004, 2:24.
216. McIntosh C.H.S. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front. Biosci. 2008, 13:1753-1773.
217. McIntosh C.H., Bremsak I., Lynn F.C., Gill R., Hinke S.A., Gelling R., Nian C., McKnight G., Jaspers S., Pederson R.A. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin. Endocrinology 1999, 140:398-404.
218. McIntosh C.H.S., Demuth H.-U., Pospisilik J.A., Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?. Regul. Pept. 2005, 128:159-165.
219. McIntosh C.H.S., Widenmaier S., Kim S.-J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam. Horm. 2009, 80:409-471.
220. McIntyre N., Holdsworth C., Turner D. New interpretation of oral glucose. Lancet 1964, II:20-21.
221. McMahon L.R., Wellman P.J. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol. Biochem. Behav. 1997, 58:673-677.
222. McMahon L.R., Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 1998, 274:R23-R29.
223. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., Abusnana S., Rossi M., Small C.J., Goldstone A.P., Taylor G.M., Sunter D., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999, 140:244-250.
224. Meier J.J., Gallwitz B., Schmidt W.E., Nauck M.A. Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives. Eur. J. Pharmacol. 2002, 440:269-279.
225. Meier J.J., Nauck M.A., Schmidt W.E., Gallwitz B. Gastric inhibitory polypeptide: The neglected incretin revisited. Regul. Pept. 2002, 107:1-13.
226. Meier J.J., Goetze O., Anstipp J., Hagemann D., Holst J.J., Schmidt W.E., Gallwitz B., Nauck M.A. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E621-E625.
227. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., Nauck M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
228. Meneilly G.S., McIntosh C.H., Pederson R.A., Habener J.F., Gingerich R., Egan J.M., Finegood D.T., Elahi D. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diab. Care 2001, 24:1951-1956.
229. Merida E., Delgado E., Molina L.M., Villanueva-Penacarrillo M.L., Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J. Clin. Endocrinol. Metab. 1993, 77:1654-1657.
230. Messenger B., Clifford M.N., Morgan L.M. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. J. Endocrinol. 2003, 177:407-412.
231. Miki H., Namba M., Nishimura T., Mineo I., Matsumura T., Miyagawa J., Nakajima H., Kuwajima M., Hanafusa T., Matsuzawa Y. Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim. Biophys. Acta 1996, 1312:132-136.
232. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., Kuroe A., Tsuda K., Hashimoto H., et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:14843-14847.
233. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
234. Moens K., Heimberg H., Flamez D., Huypens P., Quartier E., Ling Z., Pipeleers D., Gremlich S., Thorens B., Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996, 45:257-261.
235. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: Glucagon-like-peptide-1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the prefused rat pancreas. J. Clin. Invest. 1987, 79:616-619.
236. Montrose-Rafizadeh C., Yang H., Wang Y., Roth J., Montrose M.H., Adams L.G. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J. Cell. Physiol. 1997, 172:275-283.
237. Moore B., Edie E., Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem. J. 1906, 1:28-38.
238. Morales M., Lopez-Delgado M.I., Alcantara A., Luque M.A., Clemente F., Marquez L., Puente J., Vinambres C., Malaisse W.J., Villanueva-Penacarrillo M.L., Valverde I. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997, 46:1264-1269.
239. Moreno C., Mistry M., Roman R.J. Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 2002, 434:163-167.
240. Morgan L.M. The metabolic role of GIP: Physiology and pathology. Biochem. Soc. Trans. 1996, 24:585-591.
241. Mortensen K., Christensen L.L., Holst J.J., Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 2003, 114:189-196.
242. Movassat J., Beattie G.M., Lopez A.D., Hayek A. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J. Clin. Endocrinol. Metab. 2002, 87:4775-4781.
243. Murayama Y., Kawai K., Suzuki S., Ohashi S., Yamashita K. Glucagon-like peptide-1(7-37) does not stimulate either hepatic glycogenolysis or ketogenesis. Endocrinol. Jpn. 1990, 37:293-297.
244. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am. J. Physiol. 1996, 271:E808-E813.
245. Nakagawa A., Satake H., Nakabayashi H., Nishizawa M., Furuya K., Nakano S., Kigoshi T., Nakayama K., Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 2004, 110:36-43.
246. Näslund E., Gutniak M., Skogar S., Rossner S., Hellström P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J. Clin. Nutr. 1998, 68:525-530.
247. Näslund E., Gutniak M., Skogar S., Rössner S., Hellström P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J. Clin. Nutr. 1998, 68:525-530.
248. Näslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., Rossner S., Hellström P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 1999, 23:304-311.
249. Näslund E., Bogefors J., Grybäck P., Bjellerup P., Jacobsson H., Holst J.J., Hellström P.M. GLP-1 inhibits gastric emptying of water but does not influence plasma. Scand. J. Gastroenterol. 2001, 36:156-162.
250. Näslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., Hellström P.M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 2004, 91:439-446.
251. Nauck M.A., Busing M., Orskov C., Siegel E.G., Talartschik J., Baartz A., Baartz T., Hopt U.T., Becker H.D., Creutzfeldt W. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol. 1993, 30:39-45.
252. Nauck M.A., Wollschlager D., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
253. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273:E981-E988.
254. Navarro M., Rodriquez de Fonseca F., Alvarez E., Chowen J.A., Zueco J.A., Gomez R., Eng J., Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem. 1996, 67:1982-1991.
255. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.-t., Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
256. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
257. Nikolaidis L.A., Elahi D., Shen Y.-T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2401-H2408.
258. Nishizawa M., Nakabayashi H., Uchida K., Nakagawa A., Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J. Auton. Nerv. Syst. 1996, 61:149-154.
259. Nishizawa M., Nakabayashi H., Kawai K., Ito T., Kawakami S., Nakagawa A., Niijima A., Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J. Auton. Nerv. Syst. 2000, 80:14-21.
260. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., Patterson J.T., Disse E., Pfluger P.T., Lopez M., Woods S.C., DiMarchi R., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 2009, 29:5916-5925.
261. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.-M., Zhou Y.-Q., Riazi A.M., Baggio L.L., Henkelman R.M., Husain M., Drucker D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
262. Nyberg J., Anderson M.F., Meister B., Alborn A.-M., Strom A.-K., Brederlau A., Illerskog A.-C., Nilsson O., Kieffer T.J., Hietala M.A., Ricksten A., Eriksson P.S. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 2005, 25:1816-1825.
263. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 2008, 40:593-606.
264. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1209-E1215.
265. Ogawa Y., Kanai-Azuma M., Akimoto Y., Kawakami H., Yanoshita R. Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. Biol. Pharm. Bull. 2008, 31:1059-1062.
266. O'Harte F.P., Gray A.M., Abdel-Wahab Y.H., Flatt P.R. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 1997, 18:1327-1333.
267. O'Harte F.P., Gray A.M., Flatt P.R. Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J. Endocrinol. 1998, 156:237-243.
268. Ørskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123:2009-2013.
269. Pamir N., Lynn F.C., Buchan A.M., Ehses J., Hinke S.A., Pospisilik J.A., Miyawaki K., Yamada Y., Seino Y., McIntosh C.H., Pederson R.A. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E931-E939.
270. Park S., Dong X., Fisher T.L., Dunn S., Omer A.K., Weir G., White M.F. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 2006, 281:1159-1168.
271. Parnaud G., Bosco D., Berney T., Pattou F., Kerr-Conte J., Donath M.Y., Bruun C., Mandrup-Poulsen T., Billestrup N., Halban P.A. Proliferation of sorted human and rat beta cells. Diabetologia 2008, 51:91-100.
272. Pederson R.A., Brown J.C. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976, 99:780-785.
273. Pederson R.A., Brown J.C. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978, 103:610-615.
274. Pederson R.A., McIntosh C.H.S. GIP (Gastric Inhibitory Polypeptide). Encyclopedia of Endocrinology and Endocrine Diseases 2004, 202-207. Elsevier Press, Missouri, USA. L. Martini (Ed.).
275. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
276. Perley M., Kipnis D. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J. Clin. Invest. 1967, 46:1954-1962.
277. Peyot M.-L., Gray J.P., Lamontagne J., Smith P.J.S., Holz G.G., Madiraju S.R.M., Prentki M., Heart E. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PLoS ONE 2009, 4:e6221.
278. Pipeleers D. The Biosociology of pancreatic B cells. Diabetologia 1987, 30:277-291.
279. Poornima I., Brown S.B., Bhashyam S., Parikh P., Bolukoglu H., Shannon R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circulation 2008, 1:153-160.
280. Preitner F., Ibberson M., Franklin I., Binnert C., Pende M., Gjinovci A., Hansotia T., Drucker D.J., Wollheim C., Burcelin R., Thorens B. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 2004, 113:635-645.
281. Prigeon R.L., Quddusi S., Paty B., D'Alessio D.A. Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E701-E707.
282. Qin X., Shen H., Liu M., Yang Q., Zheng S., Sabo M., D'Alessio D.A., Tso P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G943-G949.
283. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
284. Redondo A., Trigo M.V., Acitores A., Valverde I., Villanueva-Penacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Mol. Cell. Endocrinol. 2003, 204:43-50.
285. Rhodes C.J. Type 2 diabetes-a matter of beta-cell life and death?. Science 2005, 307:380-384.
286. Richter G., Feddersen O., Wagner U., Barth P., Göke R., Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 1993, 265:L374-L381.
287. Rucha A., Verspohl E.J. Heterologous desensitization of insulin secretion by GIP (glucose-dependent insulinotropic peptide) in INS-1 cells: The significance of Galphai2 and investigations on the mechanism involved. Cell Biochem. Funct. 2005, 23:205-212.
288. Ruiz-Grande C., Alarcon C., Merida E., Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 1992, 13:13-16.
289. 2+ microdomains and the control of insulin secretion. Cell Calcium 2006, 40:539-551.
290. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
291. Sancho V., Trigo M.V., Gonzalez N., Valverde I., Malaisse W.J., Villanueva-Penacarrillo M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 2005, 35:27-38.
292. Sandhu H., Wiesenthal S.R., MacDonald P.E., McCall R.H., Tchipashvili V., Rashid S., Satkunarajah M., Irwin D.M., Shi Z.Q., Brubaker P.L., Wheeler M.B., Vranic M., et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999, 48:1045-1053.
293. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol. Behav. 2008, 94:670-674.
294. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J., Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008, 57:2046-2054.
295. Sarkar S., Fekete C., Legradi G., Lechan R.M. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003, 985:163-168.
296. Schäfer R., Schatz H. Stimulation of (Pro-)insulin biosynthesis and release by gastric inhibitory polypeptide in isolated islets of rat pancreas. Acta Endocrinol. 1979, 91:493-500.
297. Schirra J., Leicht P., Hildebrand P., Beglinger C., Arnold R., Goke B., Katschinski M. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J. Endocrinol. 1998, 156:177-186.
298. Schirra J., Houck P., Wank U., Arnold R., Goke B., Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000, 46:622-631.
299. Schirra J., Wank U., Arnold R., Goke B., Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002, 50:341-348.
300. Schirra J., Nicolaus M., Roggel R., Katschinski M., Storr M., Woerle H.J., Goke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006, 55:243-251.
301. Schuit F.C., Drucker D.J. Beta-cell replication by loosening the brakes of glucagon-like peptide-1 receptor signaling. Diabetes 2008, 57:529-531.
302. Scott K.A., Moran T.H. The GLP-1 agonists exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R983-R987.
303. Scrocchi L.A., Brown T.J., McClusky N., P.L.B., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996, 2:1254-1258.
304. Seeley R.J., Blake K., Rushing P.A., Benoit S., Eng J., Woods S.C., D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J. Neurosci. 2000, 20:1616-1621.
305. Seino S., Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol. Rev. 2005, 85:1303-1342.
306. Shin Y.-K., Martin B., Golden E., Dotson C.D., Maudsley S., Kim W., Jang H.-J., Mattson M.P., Drucker D.J., Egan J.M., Munger S.D. Modulation of taste sensitivity by GLP-1 signaling. J. Neurochem. 2008, 106:455-463.
307. Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.-H., McIntosh C.H.S., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009, 18:2388-2399.
308. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., Marco J. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur. J. Pharmacol. 2003, 469:195-200.
309. Singh S.K., Bartoo A.C., Krishnan S., Boylan M.O., Schwartz J.H., Michael Wolfe M. Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport. Obesity (Silver Spring) 2008, 16:2412-2416.
310. Skoglund G., Hussain M.A., Holz G.G. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 2000, 49:1156-1164.
311. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 2006, 12:694-699.
312. Song K., Zhang X., Zhao C., Ang N.T., Ma Z.A. Inhibition of calcium-independent phospholipase A2 Results in insufficient insulin secretion and impaired glucose tolerance. Mol. Endocrinol. 2005, 19:504-515.
313. Song D.H., Getty-Kaushik L., Tseng E., Simon J., Corkey B.E., Wolfe M.M. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 2007, 133:1796-1805.
314. Sonoda N., Imamura T., Yoshizaki T., Babendure J.L., Lu J.-C., Olefsky J.M. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc. Natl. Acad. Sci. USA 2008, 105:6614-6619.
315. Stoffers D.A. The development of beta-cell mass: Recent progress and potential role of GLP-1. Horm. Metab. Res. 2004, 36:811-821.
316. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., Egan J.M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.
317. Stoffers D.A., Desai B.M., DeLeon D.D., Simmons R.A. Neonatal exendin-4 prevents the development of diabetes in the intyrauterine growth retarded rat. Diabetes 2003, 52:734-740.
318. Susini S., Roche E., Prentki M., Schlegel W. Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J. 1998, 12:1173-1182.
319. 2+-dependent activation of phospholipase C in insulin-secreting cells. J. Biol. Chem. 2006, 281:28499-28507.
320. Svensson A.M., Efendic S., Ostenson C.G., Jansson L. Gastric inhibitory polypeptide and splanchnic blood perfusion: Augmentation of the islet blood flow increase in hyperglycemic rats. Peptides 1997, 18:1055-1059.
321. Szecowka J., Grill V., Sandberg E., Efendi S. Effect of GIP on the secretion of insulin and somatostatin and the accumulation of cyclic AMP in vitro in the rat. Acta Endocrinol. (Copenh) 1982, 99:416-421.
322. Tang-Christensen M., Larsen P.J., Göke R., Fink-Jensen A., Jessop D.S., Moller M., Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 1996, 271:R848-R856.
323. Tang-Christensen M., Vrang N., Larsen P.J. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int. J. Obes. Relat. Metab. Disord. 2001, 25(Suppl. 5):S42-S47.
324. Thiele T.E., Van Dijk G., Campfield L.A., Smith F.J., Burn P., Woods S.C., Bernstein I.L., Seeley R.J. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am. J. Physiol. 1997, 272:R726-R730.
325. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
326. Thorens B., Deriaz N., Bosco D., DeVos A., Pipeleers D., Schuit F., Meda P., Porret A. Protein kinase A-dependent phosphorylation of GLUT2 in pancreatic beta cells. J. Biol. Chem. 1996, 271:8075-8081.
327. Toft-Nielson M., Larsson H., Holst J.J. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects dependes on the pancreatic glucoregulatory hormones. Diabetes 1996, 45:552-556.
328. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellstrom P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig. Dis. Sci. 1998, 43:2284-2290.
329. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1: A dual receptor hypothesis. Trends Endocrinol. Metab. 2010, 21:59-67.
330. Tornehave D., Kristensen P., Romer J., Knudsen L.B., Heller R.S., Tornehave D., Kristensen P., Romer J., Knudsen L.B., Heller R.S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 2008, 56:841-851.
331. Tourrel C., Bailbe D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
332. Trümper K., Trümper A., Trüsheim H., Arnold R., Göke B., Hörsch D. Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann. N. Y. Acad. Sci. 2000, 921:242-250.
333. Trümper A., Trümper K., Trusheim H., Arnold R., Göke B., Hörsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001, 15:1559-1570.
334. Trümper A., Trümper K., Hörsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002, 174:233-246.
335. Trümper J., Ross D., Jahr H., Brendel M.D., Güke R., Hörsch D. The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells. Diabetologia 2005, 48:1534-1540.
336. Tseng C.C., Boylan M.O., Jarboe L.A., Williams E.K., Sunday M.E., Wolfe M.M. Glucose-dependent insulinotropic peptide (GIP) gene expression in the rat salivary gland. Mol. Cell. Endocrinol. 1995, 115:13-19.
337. Tseng C.C., Kieffer T.J., Jarboe L.A., Usdin T.B., Wolfe M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 1996, 98:2440-2445.
338. Tseng C.C., Zhang X.Y., Wolfe M.M. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am. J. Physiol. 1999, 276:E1049-1054.
339. 2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem. J. 2003, 369:287-299.
340. ATP null mice. Eur. J. Endocrinol. 2004, 151:407-412.
341. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
342. Unger R., Eisentraut A. Entero-insular axis. Arch. Intern. Med. 1969, 123:261-265.
343. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133:2861-2870.
344. Vahl T., D'Alessio D. Enteroinsular signaling: Perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6:461-468.
345. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., Ellis K.S., Woods S.C., Seeley R.J., Herman J.P., D'Alessio D.A. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
346. Valverde I., Morales M., Clemente F., Lopez-Delgado M.I., Delgado E., Perea A., Villanueva-Penacarrillo M.L. Glucagon-like peptide 1: A potent glycogenic hormone. FEBS Lett. 1994, 349:313-316.
347. van Dijk G., Thiele T.E. Glucagon-like peptide-1 (7-36) amide: A central regulator of satiety and interoceptive stress. Neuropeptides 1999, 33:406-414.
348. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., Long S.J., Morgan L.M., Holst J.J., Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 2001, 86:4382-4389.
349. Villanueva-Penacarrillo M.L., Alcantara A.I., Clemente F., Delgado E., Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994, 37:1163-1166.
350. Vilsbøll T. Liraglutide: A new treatment for type 2 diabetes. Drugs Today 2009, 45:101-113.
351. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114:115-121.
352. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 2007, 28:187-218.
353. Wan S., Coleman F.H.T., Travagli R.A. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1474-G1482.
354. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002, 45:1263-1273.
355. Wang Y., Kole H.K., Montrose-Rafizadeh C., Perfetti R., Bernier M., Egan J.M. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: Glucagon-like peptide-1 and insulin interactions. J. Mol. Endocrinol. 1997, 19:241-248.
356. Wang X., Cahill C.M., Pineyro M.A., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 1999, 140:4904-4907.
357. Wang Q., Li L., Xu E., Wong V., Rhodes C., Brubaker P.L. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004, 47:478-487.
358. Weaver R.E., Donnelly D., Wabitsch M., Grant P.J., Balmforth A.J. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes (Lond). 2008, 32:1705-1711.
359. Wei Y., Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol. Scand. 1996, 157:355-357.
360. Wen J., Phillips S.F., Sarr M.G., Kost L.J., Holst J.J. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am. J. Physiol. 1995, 269:G945-G952.
361. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38:665-673.
362. Wettergren A., Wojdemann M., Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am. J. Physiol. 1998, 275:G984-G992.
363. Wheeler M.B., Lu M., Dillon J.S., Leng X.-H., Chen C., Boyd A.E.I. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 1993, 133:57-62.
364. Wheeler M.B., Gelling R.W., McIntosh C.H., Georgiou J., Brown J.C., Pederson R.A. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: Ligand binding and intracellular signaling properties. Endocrinology 1995, 136:4629-4639.
365. Widenmaier S.B., Ao Z., Kim S.-J., Warnock G., McIntosh C.H.S. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J. Biol. Chem. 2009, 284:30372-30382.
366. Widenmaier S.B., Sampaio A.V., Underhill T.M., McIntosh C.H.S. Noncanonical activation of Akt/protein kinase B in β-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J. Biol. Chem. 2009, 284:10764-10773.
367. Widenmaier S.B., Kim S.-J., Yang G.K., De Los Reyes T., Nian C., Asadi A., Seino Y., Kieffer T.J., Kwok Y.N., McIntosh C.H.S. A GIP receptor agonist exhibits β-cell anti-apoptotic actions in rat models of diabetes resulting in improved β-cell function and glycemic control. PLoS ONE 2010, 5:e9590.
368. Williams D.L. Minireview: Finding the sweet spot: Peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009, 150:2997-3001.
369. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996, 81:327-332.
370. Wøjdemann M., Wettergren A., Sternby B., Holst J.J., Larsen S., Rehfeld J.F., Olsen O. Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Dig. Dis. Sci. 1998, 43:799-805.
371. Woods S.C., D'Alessio D.A. Central control of body weight and appetite. J. Clin. Endocrinol. Metab. 2008, 93(Suppl.):S37-S50.
372. Xie D., Cheng H., Hamrick M., Zhong Q., Ding K.-H., Correa D., Williams S., Mulloy A., Bollag W., Bollag R.J., Runner R.R., McPherson J.C., et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005, 37:759-769.
373. Xie D., Zhong Q., Ding K.-H., Cheng H., Williams S., Correa D., Bollag W.B., Bollag R.J., Insogna K., Troiano N., Coady C., Hamrick M., Isales C.M. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007, 40:1352-1360.
374. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
375. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Udagawa N., Takahashi N., Tanaka K., Drucker D.J., Seino Y., Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008, 149:574-579.
376. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., Hollenberg A.N., Baggio L., Saper C.B., Drucker D.J., Elmquist J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 2002, 110:43-52.
377. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., Drucker D.J., Elmquist J.K. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 2003, 23:2939-2946.
378. Yamato E., Ikegami H., Takekawa K., Fujisawa T., Nakagawa Y., Hamada Y., Ueda H., Ogihara T. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm. Metab. Res. 1997, 29:56-59.
379. Yang H., Egan J.M., Wang Y., Moyes C.D., Roth J., Montrose M.H., Montrose-Rafizadeh C. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am. J. Physiol. 1998, 275:C675-C683.
380. Yang H., Egan J.M., Rodgers B.D., Bernier M., Montrose-Rafizadeh C. Differential expression of a novel seven transmembrane domain protein in epididymal fat from aged and diabetic mice. Endocrinology 1999, 140:2859-2867.
381. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
382. Young A.A., Gedulin B.R., Rink T.J. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metab. Clin. Exp. 1996, 45:1-3.
383. Yu Z., Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell. Signal. 2010, 22:1-8.
384. Yusta B., Baggio L.L., Estall J.L., Koehler J.A., Holland D.P., Li H., Pipeleers D., Ling Z., Drucker D.J. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006, 4:391-406.
385. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.-T., Shannon R.P. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 2006, 317:1106-1113.
386. Zhong Q., Itokawa T., Sridhar S., Ding K.-H., Xie D., Kang B., Bollag W.B., Bollag R.J., Hamrick M., Insogna K., Isales C.M. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E543-E548.